Quintiles' Pike: Innovation is the path to growth

Speaking to local business leaders in Research Triangle Park, Quintiles ($Q) CEO Tom Pike said the life sciences' industry's biggest obstacle is comfort, as long-running biases in medicine can stave off innovation. For Quintiles, the world's largest CRO, growth can come only with continued investments in cutting-edge technology, Pike said. Report

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.